- Forecasts predict $55.8 billion valuation for medical cannabis market by 2025
- Pivot Pharmaceuticals building portfolio of diverse tech for improving bioavailability of cannabinoid therapies
- Company’s leadership team builds on decades of experience in pharmaceutical arena
For nutrition-conscious consumers, scanning food product labels is a requisite part of any trip to the grocery store, but a recent study by the U.S. Department of Agriculture’s Agricultural Research Service (http://ibn.fm/727E5) found that the old maxim ‘what you see isn’t always what you get’ holds true when it comes to certain foods like nuts. Even though pistachios, for example, may have 161.9 calories per ounce, only 153.8 calories are utilized by the human body. The remaining five percent of those calories are given a pass by the body and not taken up, according to the research. Such information fuels the concept of bioavailability, or determining the portion of total nutrients that the body is able to extract for use in order to establish the real benefit a consumer derives from the product.
Bioavailability becomes a similarly important question in the consumption of medications, as health researchers and physicians work to determine how much real benefit a patient derives from a drug’s properties and how to improve the body’s use of them. For companies like Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT), enhancing a drug’s bioavailability is part of their bread and butter as they not only develop products designed to improve patients’ quality of life but try to ensure that these products deliver maximum benefit to the human body’s systems.
Pivot Pharmaceuticals’ patents in the field of cannabinoid use comprise a portfolio of landmark technologies that strive to increase bioavailability, drug release rates and product stability so that consumers can “confidently take correct and accurate doses to help meet their health and wellness needs.” Some patents maintain the company’s impetus in making cannabis available through powdered formulations that can be combined with products in the food and beverage market. Through subsidiary Thrudermic (http://ibn.fm/Ru7IU), the company is invested in a transdermal lipid-based nano-dispersion technology that enhances skin absorption of cannabinoids, and the company’s water soluble, oral delivery product, PGS-N001, is designed to provide relief to cancer patients suffering from chemotherapy-induced vomiting, nausea, neutropenia and anemia by utilizing a bioavailability technology already demonstrated in Europe.
Market forecasts anticipate that the therapeutic product derivatives of cannabis will fuel a $55.8 billion market by 2025 as a growing number of governments legalize the oft-controversial drug’s use, according to a report issued last year by Grand View Research, Inc. (http://ibn.fm/L15BV).
Pivot Pharmaceuticals’ innovations in the marketplace are driven by a leadership team that’s experienced in clinical, commercial, product development and financial management. CEO Patrick Frankham has over 20 years of experience in the pharmaceutical, biopharmaceutical and services industries, leading successful development programs in oncology, and he has been a founder, investor and board member of several health care ventures during the past 15 years.
“Consumers deserve and will demand products that work, whereas regulatory authorities will require high quality, reproducible and safe products. Pivot has positioned itself to be the market leader of bio-cannabis products,” Frankham stated in summarizing the company’s mission (http://ibn.fm/IA0nv).
Board of Directors Chairman Ahmad Doroudian founded Merus Labs International Inc., and he has also filled executive positions for other pharmaceutical companies as part of his activities since becoming involved in early stage financing and management of private and publicly listed companies in the 1990s.
Dr. Wolfgang Renz, a business executive with expertise in medical innovation and cross-industry convergence, as well as a physician specializing in hepatology, serves on the board of directors, and accounting administrator Moira Ong serves as the company’s chief financial officer.
In 2017, Pivot’s Canadian leadership created a United States-based entity to take advantage of the increased legalization of the cannabis market in California and other North American locales, accelerating the monetization of the company’s Ready To Infuse Cannabis (“RTIC”) technology for products in the food and beverage industry. Pivot Naturals, LLC is led by President Pat Rolfes and Director of Research and Development Ross Franklin. Rolfes and Franklin led RTIC developer ERS Holdings LLC prior to the acquisition of that company and its patents by Pivot, and they are joined on the Pivot USA executive team by product formulation administrators Joseph Borovsky and Leonid Lurya, who were the scientific technology executives on the Thrudermic team upon its acquisition.
For more information, visit the company’s website at www.PivotPharma.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
QualityStocks (QS)
Scottsdale, Arizona
www.qualitystocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php
